Analysts Set Century Therapeutics, Inc. (NASDAQ:IPSC) Price Target at $3.75

Shares of Century Therapeutics, Inc. (NASDAQ:IPSC) have been given an average rating of “Moderate Buy” by the five ratings firms that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $3.75.

Several brokerages recently issued reports on IPSC. Weiss Ratings reissued a “sell (e+)” rating on shares of Century Therapeutics in a research note on Saturday, September 27th. Wall Street Zen downgraded Century Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday.

Century Therapeutics Trading Up 0.6%

Shares of Century Therapeutics stock opened at $0.56 on Friday. The stock has a 50-day moving average price of $0.52 and a 200 day moving average price of $0.54. The company has a market cap of $48.26 million, a P/E ratio of -1.93 and a beta of 1.78. Century Therapeutics has a 1 year low of $0.34 and a 1 year high of $1.83.

Century Therapeutics (NASDAQ:IPSC) last announced its quarterly earnings data on Thursday, August 14th. The company reported ($0.38) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.38). Century Therapeutics had a negative return on equity of 11.53% and a negative net margin of 19.10%. On average, equities analysts forecast that Century Therapeutics will post -1.61 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Century Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Jane Street Group LLC raised its stake in shares of Century Therapeutics by 166.2% during the 4th quarter. Jane Street Group LLC now owns 48,036 shares of the company’s stock worth $49,000 after purchasing an additional 29,992 shares in the last quarter. Bank of America Corp DE raised its stake in shares of Century Therapeutics by 109.1% during the 4th quarter. Bank of America Corp DE now owns 66,043 shares of the company’s stock worth $67,000 after purchasing an additional 34,466 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Century Therapeutics by 26.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 179,635 shares of the company’s stock valued at $86,000 after acquiring an additional 38,052 shares during the last quarter. Prudential Financial Inc. acquired a new position in shares of Century Therapeutics during the 2nd quarter valued at about $25,000. Finally, Two Sigma Advisers LP acquired a new position in shares of Century Therapeutics during the 4th quarter valued at about $52,000. 50.20% of the stock is owned by hedge funds and other institutional investors.

About Century Therapeutics

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.